Vimarsana
Biggest News Aggregation in the World

Page 9 - Higher Than News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Higher Than. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Higher Than Today - Breaking & Trending Today

The Myths Among Us: Frances Boyle's Openwork and Limestone - Vimarsana News

The Myths Among Us: Frances Boyle's Openwork and Limestone

The poems of Openwork and Limestone draw us down and back. But “that which won’t stay buried rises,” asks “what flows unseen beneath our lives?” (“Inhumed”).This is the dangerous and thrilling question posed by Boyle’s technically superb, fearlessly probing volume. The title and cover image are inspired. Openwork is meticulous…

Pollution Levels In Delhi Nearly 100 Times Higher Than WHO Limits - Vimarsana News

Pollution Levels In Delhi Nearly 100 Times Higher Than WHO Limits

Delhi's air quality plummeted to the 'severe plus' category again, making the national capital the most polluted city in the country today. The real-time Air Quality Index (AQI) is over 500 in different parts of the capital.

Source: ndtv.com
More families growing food at home to save money due to inflation - Vimarsana News

More families growing food at home to save money due to inflation

Expiring COVID-19 food assistance programs and inflation continue to keep families from finding affordable food at the grocery store, and that's led some families to start growing their food at home.

Source: wptv.com
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease (CTAD) Conference -October 25, 2023 at 05:27 pm EDT - Vimarsana News

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease (CTAD) Conference -October 25, 2023 at 05:27 pm EDT

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical...

EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE - Vimarsana News

EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS 11% HIGHER, AND SIMILAR ARIA RATES TO IV 76% OF PATIENTS SHOWED NO DECLINE AND 60% SHOWED CLINICAL...